Compile Data Set for Download or QSAR
Report error Found 14 Enz. Inhib. hit(s) with all data for entry = 10585
TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552588(WO2022101184, Example 1 | N-[2-({4-[3-(3-chloro-2-...)
Affinity DataIC50: 0.160nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552593(WO2022101184, Example 6 | N-[2-({4-[3-(3-fluoro-2-...)
Affinity DataIC50: 0.170nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552600(WO2022101184, Example 13 | 3-(3-chloro-2-methoxyan...)
Affinity DataIC50: 0.210nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552592(WO2022101184, Example 5 | N-[2-({4-[3-(3-chloro-2-...)
Affinity DataIC50: 0.230nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552590(WO2022101184, Example 3 | N-[2-({4-[3-(3-chloro-2-...)
Affinity DataIC50: 0.270nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552591(WO2022101184, Example 4 | N-[3-({4-[3-(3-chloro-2-...)
Affinity DataIC50: 0.310nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552589(WO2022101184, Example 2 | N-[2-({4-[3-(3-fluoro-2-...)
Affinity DataIC50: 0.390nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552598(WO2022101184, Example 11 | N-[2-({4-[3'-(3-chloro-...)
Affinity DataIC50: 0.460nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552595(WO2022101184, Example 8 | (2E)-4-(dimethylamino)-N...)
Affinity DataIC50: 0.550nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552601(WO2022101184, Example 14 | N-(2-{[4-(3-{[2-(difluo...)
Affinity DataIC50: 0.570nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552599(WO2022101184, Example 12 | N-[2-({4-[3-(3-chloro-2...)
Affinity DataIC50: 0.580nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552594(WO2022101184, Example 7 | N-[2-({4-[3-(4-fluoroani...)
Affinity DataIC50: 1.62nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552596(WO2022101184, Example 9 | (2E)-N-[2-({4-[3-(3-chlo...)
Affinity DataIC50: 2.48nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184

TargetEpidermal growth factor receptor [669-770,'SVD',771-1210](Human)
Bayer Aktiengesellschaft

WIPO
LigandPNGBDBM552597(WO2022101184, Example 10 | (2E)-N-[2-({4-[3'-(3-ch...)
Affinity DataIC50: 3.55nMAssay Description: Inhibitory activity of compounds of the present invention against an Epidermal Growth Factor Receptor (EGFR) with an insertion of the amino acids se...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101184